Table 2 Clinical, functional, radiological and histopathological characteristics of CPFE patients according to their immunologic profile
From: Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema
Variable | ANA + ANCA+ | ANA + ANCA- | ANA-ANCA- |
|---|---|---|---|
Total Number | 7 | 10 | 23 |
FEV1%pred | 69,2 ± 17,1 | 67,8 ± 14,3 | 68,4 ± 18,7 |
FVC%pred | 72,87 ± 26,6 | 68,96 ± 22,9 | 69,54 ± 21,6 |
DLCO%pred | 35,95 ± 12,3 | 35,79 ± 10,7 | 33,9 ± 10,4 |
Histopathology pattern | UIP | UIP | UIP |
CD20 + cells/mm2 | 51.6 ± 6.9* | 49.6 ± 7.1* | 6.2 ± 3.6 |
Survival (median-range) months | 51 (12 – 96)* | 38 (16 – 61) | |
Radiology pattern | UIP | UIP | UIP |
sPAP | 36,9 ± 13,1 | 38,2 ± 12,8 | 37,1 ± 11,5 |
Hemoptysis | 7 | 0 | 0 |
Hematuria | 7 | 0 | 0 |
Arthralgias | 0 | 3 | 0 |
Raynaud’s phenomenon | 0 | 4 | 0 |
Dysphagia | 0 | 1 | 0 |